Tennessee Cancer Specialists (TCS), an East Tennessee oncology group, has partnered with Sarah Cannon Research Institute (SCRI), a leading oncology research organization. This collaboration will expand research options for cancer patients in the region.
TCS physicians have long recognized the importance of clinical trials and have referred eligible patients to SCRI in Nashville. Now, patients can access novel therapies closer to home. TCS is Tennessee’s third-largest oncology practice, with 12 physicians across 15 locations.
Dee Anna Smith, CEO of SCRI, indicated that they aim to bring clinical trials into the community and that eligible patients can access innovative therapies without traveling, enabling them to stay close to their support systems.
SCRI’s network includes over 1,300 physicians conducting clinical trials at more than 250 locations nationwide. Since its inception, SCRI has contributed to research that has led to most FDA-approved cancer therapies.
TCS will begin offering SCRI clinical trials in the summer of 2024. For more information, visit www.tncancer.com.
TCS is the largest private, independent cancer practice in East Tennessee. Established in 2004, TCS provides compassionate, individualized care to cancer patients. Its mission is to meet their unique needs and assist them and their families throughout their recovery journey.
SCRI is a globally renowned oncology research organization dedicated to advancing cancer therapies. In 2022, SCRI partnered with former US Oncology Research to expand clinical trial access nationwide. SCRI has conducted numerous first-in-human clinical trials and played a crucial role in developing many FDA-approved cancer therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
